267 related articles for article (PubMed ID: 30333122)
1. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.
Lilleness B; Ruberg FL; Mussinelli R; Doros G; Sanchorawala V
Blood; 2019 Jan; 133(3):215-223. PubMed ID: 30333122
[TBL] [Abstract][Full Text] [Related]
2. Validation of the Boston University staging system in AL amyloidosis.
Tomlinson R; Matigian N; Mollee P
Amyloid; 2019 Sep; 26(3):125-127. PubMed ID: 31145007
[No Abstract] [Full Text] [Related]
3. Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study.
Zaroui A; Kharoubi M; Gounot R; Oghina S; Degoutte C; Bezard M; Galat A; Guendouz S; Roulin L; Audard V; Leroy V; Teiger E; Poullot E; Molinier-Frenkel V; Le Bras F; Belhadj K; Bastard JP; Fellahi S; Shourick J; Lemonier F; Damy T
ESC Heart Fail; 2024 Jun; 11(3):1707-1719. PubMed ID: 38444090
[TBL] [Abstract][Full Text] [Related]
4. [The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients - single center experience].
Pika T; Lochman P; Vymětal J; Metelka R; Flodr P; Minařík J; Látalová P; Zapletalová J; Bačovský J; Sčudla V
Vnitr Lek; 2013 Sep; 59(9):776-81. PubMed ID: 24073949
[TBL] [Abstract][Full Text] [Related]
5. Prognostic values of novel biomarkers in patients with AL amyloidosis.
Kim D; Lee GY; Choi JO; Kim K; Kim SJ; Ju ES; Jeon ES
Sci Rep; 2019 Aug; 9(1):12200. PubMed ID: 31434944
[TBL] [Abstract][Full Text] [Related]
6. Establishment of brain natriuretic peptide - based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis.
Lilleness B; Doros G; Ruberg FL; Sanchorawala V
Br J Haematol; 2020 Feb; 188(3):424-427. PubMed ID: 31515797
[TBL] [Abstract][Full Text] [Related]
7. Utility of B-Type Natriuretic Peptide for Detecting Cardiac Involvement in Immunoglobulin Amyloidosis.
Kimishima Y; Yoshihisa A; Kiko T; Yokokawa T; Miyata-Tatsumi M; Misaka T; Oikawa M; Kobayashi A; Takeishi Y
Int Heart J; 2019 Sep; 60(5):1106-1112. PubMed ID: 31484874
[TBL] [Abstract][Full Text] [Related]
8. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
Kumar S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Colby C; Laumann K; Zeldenrust SR; Leung N; Dingli D; Greipp PR; Lust JA; Russell SJ; Kyle RA; Rajkumar SV; Gertz MA
J Clin Oncol; 2012 Mar; 30(9):989-95. PubMed ID: 22331953
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
10. Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design.
Vaxman I; Kumar SK; Buadi F; Lacy MQ; Dingli D; Hwa Y; Fonder A; Hobbs M; Hayman S; Kourelis T; Warsame R; Muchtar E; Leung N; Kapoor P; Grogan M; Go R; Lin Y; Gonsalves W; Siddiqui M; Kyle RA; Rajkumar SV; Gertz MA; Dispenzieri A
Leukemia; 2021 Dec; 35(12):3604-3607. PubMed ID: 34021252
[No Abstract] [Full Text] [Related]
11. Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).
Kristen AV; Maurer MS; Rapezzi C; Mundayat R; Suhr OB; Damy T;
PLoS One; 2017; 12(4):e0173086. PubMed ID: 28384285
[TBL] [Abstract][Full Text] [Related]
12. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.
Dispenzieri A; Gertz MA; Saenger A; Kumar SK; Lacy MQ; Buadi FK; Dingli D; Leung N; Zeldenrust S; Hayman SR; Kapoor P; Grogan M; Hwa L; Russell SJ; Go RS; Rajkumar SV; Kyle RA; Jaffe A
Am J Hematol; 2015 Jun; 90(6):524-8. PubMed ID: 25753178
[TBL] [Abstract][Full Text] [Related]
13. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
Dispenzieri A; Gertz MA; Kyle RA; Lacy MQ; Burritt MF; Therneau TM; Greipp PR; Witzig TE; Lust JA; Rajkumar SV; Fonseca R; Zeldenrust SR; McGregor CG; Jaffe AS
J Clin Oncol; 2004 Sep; 22(18):3751-7. PubMed ID: 15365071
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.
Aljama MA; Sidiqi MH; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame RM; Kourelis T; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Blood Adv; 2019 Apr; 3(8):1226-1229. PubMed ID: 30975646
[TBL] [Abstract][Full Text] [Related]
15. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters.
Lei C; Zhu X; Hsi DH; Wang J; Zuo L; Ta S; Yang Q; Xu L; Zhao X; Wang Y; Sun S; Liu L
BMC Cardiovasc Disord; 2021 Jan; 21(1):43. PubMed ID: 33478398
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
17. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.
Dispenzieri A; Gertz MA; Kumar SK; Lacy MQ; Kyle RA; Saenger AK; Grogan M; Zeldenrust SR; Hayman SR; Buadi F; Greipp PR; Leung N; Russell SR; Dingli D; Lust JA; Rajkumar SV; Jaffe AS
Heart; 2014 Mar; 100(5):383-8. PubMed ID: 24402772
[TBL] [Abstract][Full Text] [Related]
18. Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin.
Kumar SK; Gertz MA; Dispenzieri A
J Clin Oncol; 2019 Jan; 37(2):171-173. PubMed ID: 30433848
[No Abstract] [Full Text] [Related]
19. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
20. A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in Japan.
Fuchida SI; Ide D; Taminishi-Katsuragawa Y; Suga T; Matsui-Maegawa S; Maruyama N; Iwamura Y; Kitamura Y; Okawa Y; Okano A; Hatsuse M; Murakami S; Shimazaki C
Int J Hematol; 2020 Jun; 111(6):803-811. PubMed ID: 32020505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
